Behavioral factors, fragmented care, and systemic barriers disproportionately impact obesity patients, making long-term adherence difficult
September 2025: Pfizer announced its agreement to acquire Metsera in a deal valued at up to USD 7.3 billion, strengthening its pipeline of next-generation GLP-1, amylin, and obesity therapies
GIP agonism Supports insulin response, improves blood sugar control, and helps regulate appetite
Insurers raised cost-sharing sharply for GLP-1s in recent years, Klebanoff found
For example, Novo Nordisk has listed 21 device patents in the Orange Book for Ozempic, accounting for 84% of its total patent listings
At best, a GLP-1 supplement might expand on the effects of foods generally considered good for you, including unsaturated fats from avocados, nuts, flaxseed, and olive oil